Cardiovascular effects of coxibs

Abstract

A new class of drugs, the selective cyclooxygenase-2 (COX-2) inhibitors, or coxibs, have recently been marketed as an alternative to conventional nonsteroidal anti-inflammatory drugs (NSAIDs) on the basis of a lower risk of gastrointestinal side effects. The recent withdrawal of rofecoxib, along with safety concerns about other COX-2 selective inhibitors raises important questions about the cardiovascular toxicity of these drugs. Recently some concerns arose even for a possible cardiotoxicity of nonselective nonsteroidal anti-inflammatory drugs. From data available so far, it seems that coxibs still remain a rational choice for patients with low cardiovascular risk and high gastrointestinal risk. Long-term studies with a cardiovascular endpoint involving both selective and nonselective anti-inflammatory drugs are warranted.

Keywords

celecoxib myocardial infarction nonsteroidal anti-inflammatory drugs rofecoxib

Get full access to this article

View all access options for this article.

References

Wolfe MM , Lichtenstein DR , Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs . N Engl J Med 1999; 341: 1397-1399 .

Marnett LJ , Rowlinson SW , Goodwin DC , Kalgutkar AS , Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition . J Biol Chem 1999; 274: 22903-22906 .

Silverstein FE , Faich G , Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial . JAMA 2000; 284: 1247-1255 .

Bombardier C , Laine L , Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis . N Engl J Med 2000; 343: 1520-1528 .

Ray WA , MacDonald TM , Solomon DH , Graham DJ , Avorn J. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease . Pharmacoepidemiol Drug Safety 2003; 12: 67-70 .

Psaty BM , Furberg CD. COX-2 inhibitors. Lessons in drug safety . N Engl J Med 2005; 352: 1133-1134 .

Drazen JM. COX-2 inhibitors. A lesson in unexpected problems . N Engl J Med 2005; 352: 1131-1132 .

Juni P , Nartey L , Reichenbach S , Sterchi R , Dieppe PA , Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis . Lancet 2004; 364: 2021-2029 .

Farkouh ME , Kirshner H , Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial . Lancet 2004; 364: 675-684 .

10.

Bresalier RS , Sandler RS , Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl J Med 2005; 352: 1092-1102 .

11.

Solomon SD , McMurray JJV , Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention . N Engl J Med 2005; 352: 1071-1080 .

12.

Ott E , Nussmeier NA , Duke PC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery . J Thorac Cardiovasc Surg 2003; 125: 1481-1492 .

13.

Nussmeier NA , Whelton AA , Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery . N Engl J Med 2005; 352: 1081-1091 .

14.

Fitzgerald GA , Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med 2001; 345: 433-442 .

15.

Baigent C , Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin and cardiovascular disease. A reappraisal . Arthritis Rheum 2003; 48: 12-20 .

16.

Chenevard R , Hurlimann D , Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease . Circulation 2003; 107: 405-409 .

17.

Okie S. Rising the safety bar - The FDA’s coxib meeting . N Engl J Med 2005; 352: 1283-1285 .

18.

Hippisley-Cox J , Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis . BMJ 2005; 330: 1366-1366 .

19.

Choi HK , Seeger JD , Kuntz KM. Effects of Rofecoxib and Naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis . Am J Med 2004; 116: 621-629 .